ClearPoint Neuro Inc.
CLPT | NASDAQ
$15.03
+$1.06 (+7.59%)
Sep 22, 2026, 2:01 PM ET · Market open
Company Profile
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Key Executives
| Name | Position |
|---|---|
| Joseph Michael Burnett | President, Chief Executive Officer & Director |
| Danilo D'Alessandro | Chief Financial Officer |
| Mazin Sabra | Chief Operating Officer |
| Ellisa Cholapranee | General Counsel & Secretary |
| Jeremy Stigall | Chief Business Officer |
| Mary McNamara-Cullinane | Senior Vice President of Regulatory Affairs |
| Megan Faulkenberry | Senior Vice President of Quality |
| Paul S. Larson FAANS | Chief Medical Officer |
| Robert C. Korn | Senior Vice President of Sales & Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Aug 12, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 04, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 03, 2026 | 10-Q | Quarterly Report |
| Aug 03, 2026 | 8-K | Current Report |
| Jul 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 06, 2026 | 4 | Filing |
| Jul 06, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
ClearPoint Neuro Inc.
| Country | United States |
| IPO Date | May 21, 2012 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 172 |
| CEO | Joseph Michael Burnett |
Contact Details
120 S. Sierra Avenue Solana Beach,
California 92075 United States
Stock Details
| Ticker Symbol | CLPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001285550 |
| CUSIP Number | 18507C103 |
| ISIN Number | US18507C1036 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove CLPT